{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T04:55:41Z","timestamp":1790052941077,"version":"4.0.1"},"reference-count":69,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T00:00:00Z","timestamp":1738281600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Fundaci\u00f3n Reina Sof\u00eda"},{"DOI":"10.13039\/100008054","name":"Fundaci\u00f3n Ram\u00f3n Areces","doi-asserted-by":"publisher","award":["E.6.4 FRS-CUERPOS DE LEWY"],"award-info":[{"award-number":["E.6.4 FRS-CUERPOS DE LEWY"]}],"id":[{"id":"10.13039\/100008054","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Sara Borrell","award":["CD21\/00067"],"award-info":[{"award-number":["CD21\/00067"]}]},{"name":"Miguel Servet","award":["CP19\/00031"],"award-info":[{"award-number":["CP19\/00031"]}]},{"DOI":"10.13039\/501100004587","name":"ISCIII","doi-asserted-by":"publisher","award":["PMP22\/00022"],"award-info":[{"award-number":["PMP22\/00022"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"ISCIII","doi-asserted-by":"publisher","award":["PI20\/01011"],"award-info":[{"award-number":["PI20\/01011"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"ISCIII","doi-asserted-by":"publisher","award":["TED2021-131676B-100"],"award-info":[{"award-number":["TED2021-131676B-100"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004063","name":"Knut and Alice Wallenberg Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004063","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017018","name":"Wallenberg Centre for Molecular and Translational Medicine","doi-asserted-by":"publisher","award":["KAW2014.0363"],"award-info":[{"award-number":["KAW2014.0363"]}],"id":[{"id":"10.13039\/501100017018","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"publisher","award":["2017\u201302869 2021\u201302678"],"award-info":[{"award-number":["2017\u201302869 2021\u201302678"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"publisher","award":["2021\u201306545"],"award-info":[{"award-number":["2021\u201306545"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Swedish government and the County Councils","award":["ALFGBG-813971"],"award-info":[{"award-number":["ALFGBG-813971"]}]},{"name":"Swedish government and the County Councils","award":["ALFGBG-965326"],"award-info":[{"award-number":["ALFGBG-965326"]}]},{"DOI":"10.13039\/501100003792","name":"Swedish Brain Foundation","doi-asserted-by":"publisher","award":["FO2021\u20130311"],"award-info":[{"award-number":["FO2021\u20130311"]}],"id":[{"id":"10.13039\/501100003792","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Swedish Alzheimer Foundation","award":["AF-740191"],"award-info":[{"award-number":["AF-740191"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Lewy body (LB) pathology is present as a co-pathology in \u223c50% of patients with Alzheimer\u2019s disease (AD) and may even represent the main neuropathologic substrate in a subset of patients with amnestic impairments. However, the degree to which LB pathology affects regional neurodegeneration patterns and clinical trajectories among amnestic patients is not well understood.<\/jats:p>\n               <jats:p>We studied 865 patients from the Alzheimer\u2019s Disease Neuroimaging Initiative cohort with clinical diagnoses of amnestic mild cognitive impairment (n = 661) or AD dementia (n = 211), who had CSF and FDG-PET data available. CSF samples were analysed for peptide levels of amyloid-\u03b21\u201342 and p-tau181, and \u03b1Syn positivity was evaluated using a novel \u03b1-synuclein seed amplification assay. Based on positive\/negative results on the different biomarkers, subjects were classified as \u2018AD\u2212LB\u2212\u2019 (n = 304), \u2018AD+LB\u2212\u2019 (n = 335), \u2018AD+LB+\u2019 (n = 158) and \u2018AD\u2212LB+\u2019 (n = 68). We analysed group differences in regional FDG-PET patterns, demographics, APOE4 genotype, baseline and longitudinal domain-specific cognitive profiles (memory versus executive function\/visuospatial performance), and risk for developing hallucinations.<\/jats:p>\n               <jats:p>AD+LB+ showed worse global cognition (Mini-Mental State Examination: P = 0.005) and declined faster (P &amp;lt; 0.001) than AD+LB\u2212, but both groups exhibited similar memory-predominant cognitive profiles. In FDG-PET, AD+LB+ showed more severe hypometabolism compared to AD+LB\u2212, but both groups were characterized by largely identical patterns of temporo-parietal hypometabolism. By contrast, AD\u2212LB+ were less globally impaired (P &amp;lt; 0.001) but characterized by a markedly more dysexecutive and visuospatial profile (P &amp;lt; 0.003) and a strikingly different posterior-occipital pattern of hypometabolism. APOE4 positivity was similar between AD+LB+ and AD+LB\u2212 (72% versus 75%, P = 0.28) but lower in AD\u2212LB+ (28%, P &amp;lt; 0.001). On a group level, AD+LB+, AD+LB\u2212 and AD\u2212LB+ showed similar risks of developing hallucinations, but patients with LB-like posterior-occipital hypometabolism had a significantly higher risk compared to those showing an AD-typical temporo-parietal pattern (hazard ratio = 2.58, P = 0.004).<\/jats:p>\n               <jats:p>In conclusion, LB co-pathology in AD was associated with more severe hypometabolism and faster cognitive decline, but did not affect the regional hypometabolic pattern or cognitive profile. By contrast, patients with relatively pure LB pathology showed a more executive\/visuospatial-predominant cognitive profile and a distinct posterior-occipital hypometabolism pattern characteristic for LB disease. These findings indicate that the presence of LB pathology may have different consequences for the clinical phenotype depending on AD co-morbidity, which may have critical implications for accurate diagnosis and prognosis of patients presenting with amnestic syndromes.<\/jats:p>","DOI":"10.1093\/brain\/awaf037","type":"journal-article","created":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T16:17:52Z","timestamp":1738340272000},"page":"2441-2452","source":"Crossref","is-referenced-by-count":15,"title":["The effect of Lewy body (co-)pathology on the clinical and imaging phenotype of amnestic patients"],"prefix":"10.1093","volume":"148","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5196-0103","authenticated-orcid":false,"given":"Jes\u00fas","family":"Silva-Rodr\u00edguez","sequence":"first","affiliation":[{"name":"Reina Sofia Alzheimer Centre, CIEN Foundation, ISCIII , Madrid 28031 ,","place":["Spain"]},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red sobre Enfermedades Neurodegenerativas (CIBERNED) , Madrid 28029 ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel A","family":"Labrador-Espinosa","sequence":"additional","affiliation":[{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red sobre Enfermedades Neurodegenerativas (CIBERNED) , Madrid 28029 ,","place":["Spain"]},{"name":"Wallenberg Center for Molecular and Translational Medicine and Department of Psychiatry and Neurochemistry, University of Gothenburg , Gothenburg 405 30 ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Zhang","sequence":"additional","affiliation":[{"name":"Reina Sofia Alzheimer Centre, CIEN Foundation, ISCIII , Madrid 28031 ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Castro-Labrador","sequence":"additional","affiliation":[{"name":"Reina Sofia Alzheimer Centre, CIEN Foundation, ISCIII , Madrid 28031 ,","place":["Spain"]},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red sobre Enfermedades Neurodegenerativas (CIBERNED) , Madrid 28029 ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco Javier","family":"L\u00f3pez-Gonz\u00e1lez","sequence":"additional","affiliation":[{"name":"Reina Sofia Alzheimer Centre, CIEN Foundation, ISCIII , Madrid 28031 ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0170-036X","authenticated-orcid":false,"given":"Alexis","family":"Moscoso","sequence":"additional","affiliation":[{"name":"Wallenberg Center for Molecular and Translational Medicine and Department of Psychiatry and Neurochemistry, University of Gothenburg , Gothenburg 405 30 ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascual","family":"S\u00e1nchez-Juan","sequence":"additional","affiliation":[{"name":"Reina Sofia Alzheimer Centre, CIEN Foundation, ISCIII , Madrid 28031 ,","place":["Spain"]},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red sobre Enfermedades Neurodegenerativas (CIBERNED) , Madrid 28029 ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7800-1781","authenticated-orcid":false,"given":"Michael","family":"Sch\u00f6ll","sequence":"additional","affiliation":[{"name":"Wallenberg Center for Molecular and Translational Medicine and Department of Psychiatry and Neurochemistry, University of Gothenburg , Gothenburg 405 30 ,","place":["Sweden"]},{"name":"Dementia Research Centre, Queen Square Institute of Neurology, University College London , London WC1E 6BT ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel J","family":"Grothe","sequence":"additional","affiliation":[{"name":"Reina Sofia Alzheimer Centre, CIEN Foundation, ISCIII , Madrid 28031 ,","place":["Spain"]},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red sobre Enfermedades Neurodegenerativas (CIBERNED) , Madrid 28029 ,","place":["Spain"]},{"name":"Wallenberg Center for Molecular and Translational Medicine and Department of Psychiatry and Neurochemistry, University of Gothenburg , Gothenburg 405 30 ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,1,31]]},"reference":[{"key":"2025070715514440400_awaf037-B1","doi-asserted-by":"crossref","first-page":"5143","DOI":"10.1002\/alz.13859","article-title":"Revised criteria for diagnosis and staging of Alzheimer\u2019s disease: Alzheimer\u2019s association workgroup","volume":"20","author":"Jack","year":"2024","journal-title":"Alzheimer\u2019s Dementia"},{"key":"2025070715514440400_awaf037-B2","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/S1474-4422(21)00066-1","article-title":"Clinical diagnosis of Alzheimer\u2019s disease: Recommendations of the international working group","volume":"20","author":"Dubois","year":"2021","journal-title":"Lancet Neurol."},{"key":"2025070715514440400_awaf037-B3","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1002\/alz.13355","article-title":"The impact of tau deposition and hypometabolism on cognitive impairment and longitudinal cognitive decline","volume":"20","author":"Boccalini","year":"2024","journal-title":"Alzheimer\u2019s Dementia"},{"key":"2025070715514440400_awaf037-B4","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1212\/WNL.0000000000004058","article-title":"Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium","volume":"89","author":"McKeith","year":"2017","journal-title":"Neurology"},{"issue":"Supplement 1","key":"2025070715514440400_awaf037-B5","doi-asserted-by":"crossref","first-page":"2S","DOI":"10.2967\/jnumed.121.263194","article-title":"18 F-FDG PET imaging in neurodegenerative dementing disorders: Insights into subtype classification, emerging disease categories, and mixed dementia with copathologies","volume":"63","author":"Minoshima","year":"2022","journal-title":"J Nucl Med"},{"key":"2025070715514440400_awaf037-B6","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1111\/ene.13728","article-title":"European association of nuclear medicine and European Academy of Neurology recommendations for the use of brain 18 F-fluorodeoxyglucose positron emission tomography in neurodegenerative cognitive impairment and dementia: Delphi consensus","volume":"25","author":"Nobili","year":"2018","journal-title":"Euro J of Neurology"},{"key":"2025070715514440400_awaf037-B7","doi-asserted-by":"crossref","first-page":"102754","DOI":"10.1016\/j.nicl.2021.102754","article-title":"FDG PET metabolic signatures distinguishing prodromal DLB and prodromal AD","volume":"31","author":"Kantarci","year":"2021","journal-title":"Neuroimage Clin."},{"key":"2025070715514440400_awaf037-B8","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1093\/brain\/awaa438","article-title":"The development and convergence of co-pathologies in Alzheimer\u2019s disease","volume":"144","author":"Robinson","year":"2021","journal-title":"Brain"},{"key":"2025070715514440400_awaf037-B9","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/ane.13028","article-title":"Lewy body pathology in Alzheimer\u2019s disease: A clinicopathological prospective study","volume":"139","author":"Savica","year":"2019","journal-title":"Acta Neurol Scand"},{"key":"2025070715514440400_awaf037-B10","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s13195-018-0356-0","article-title":"Improving the identification of dementia with Lewy bodies in the context of an Alzheimer\u2019s-type dementia","volume":"10","author":"Thomas","year":"2018","journal-title":"Alz Res Therapy"},{"key":"2025070715514440400_awaf037-B11","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/WCO.0000000000000912","article-title":"What is \u201cAlzheimer\u2019s disease\u201d? The neuropathological heterogeneity of clinically defined Alzheimer\u2019s dementia","volume":"34","author":"Mehta","year":"2021","journal-title":"Curr Opin Neurol"},{"key":"2025070715514440400_awaf037-B12","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1001\/archneur.63.5.665","article-title":"Neuropathologic features of amnestic mild cognitive impairment","volume":"63","author":"Petersen","year":"2006","journal-title":"Arch Neurol"},{"key":"2025070715514440400_awaf037-B13","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/s12883-015-0403-4","article-title":"Neuropathological comparisons of amnestic and nonamnestic mild cognitive impairment","volume":"15","author":"Dugger","year":"2015","journal-title":"BMC Neurol"},{"key":"2025070715514440400_awaf037-B14","doi-asserted-by":"crossref","first-page":"274","DOI":"10.2967\/jnumed.122.264213","article-title":"Differential effects of tau stage, Lewy body pathology, and substantia nigra degeneration on 18F-DG PET patterns in clinical Alzheimer Disease","volume":"64","author":"Silva-Rodriguez","year":"2023","journal-title":"J Nucl Med."},{"key":"2025070715514440400_awaf037-B15","doi-asserted-by":"crossref","DOI":"10.1093\/braincomms\/fcae183","article-title":"Clinical criteria for a limbic-predominant amnestic neurodegenerative syndrome","volume":"6","author":"Corriveau-Lecavalier","year":"2024","journal-title":"Brain Commun"},{"key":"2025070715514440400_awaf037-B16","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1093\/brain\/aws234","article-title":"Cognitive impairment, decline and fluctuations in older community-dwelling subjects with Lewy bodies","volume":"135","author":"Schneider","year":"2012","journal-title":"Brain"},{"key":"2025070715514440400_awaf037-B17","doi-asserted-by":"crossref","first-page":"e0217566","DOI":"10.1371\/journal.pone.0217566","article-title":"Faster cognitive decline in dementia due to Alzheimer disease with clinically undiagnosed Lewy body disease","volume":"14","author":"Malek-Ahmadi","year":"2019","journal-title":"PLoS One"},{"key":"2025070715514440400_awaf037-B18","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1001\/jamaneurol.2015.0606","article-title":"Clinical features of Alzheimer disease with and without Lewy bodies","volume":"72","author":"Chung","year":"2015","journal-title":"JAMA Neurol"},{"key":"2025070715514440400_awaf037-B19","doi-asserted-by":"crossref","first-page":"e12189","DOI":"10.1002\/dad2.12189","article-title":"Clinico-pathological comparison of patients with autopsy-confirmed Alzheimer\u2019s disease, dementia with Lewy bodies, and mixed pathology","volume":"13","author":"Chatterjee","year":"2021","journal-title":"Alzheimers Dement (Amst)"},{"key":"2025070715514440400_awaf037-B20","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1212\/WNL.0000000000004567","article-title":"Mixed neuropathologies and associations with domain-specific cognitive decline","volume":"89","author":"Brenowitz","year":"2017","journal-title":"Neurology"},{"key":"2025070715514440400_awaf037-B21","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1002\/alz.12120","article-title":"Cognitive tests aid in clinical differentiation of Alzheimer\u2019s disease versus Alzheimer\u2019s disease with Lewy body disease: Evidence from a pathological study","volume":"16","author":"Azar","year":"2020","journal-title":"Alzheimers Dement"},{"issue":"S18","key":"2025070715514440400_awaf037-B22","doi-asserted-by":"crossref","first-page":"e079470","DOI":"10.1002\/alz.079470","article-title":"Associations between neuropsychiatric symptoms, pathology in neuropathological cohorts of Alzheimer\u2019s disease, Alzheimer\u2019s disease with Lewy bodies and Dementia with Lewy bodies","volume":"19","author":"Tremblay","year":"2023","journal-title":"Alzheimer\u2019s & Dementia"},{"key":"2025070715514440400_awaf037-B23","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.3233\/JAD-170914","article-title":"Influence of Lewy pathology on Alzheimer\u2019s disease phenotype: A retrospective clinico-pathological study","volume":"63","author":"Roudil","year":"2018","journal-title":"Alzheimers disease"},{"key":"2025070715514440400_awaf037-B24","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.3233\/JAD-201187","article-title":"Cognition at each stage of Lewy body disease with co-occurring Alzheimer\u2019s disease pathology1","volume":"80","author":"Ryman","year":"2021","journal-title":"J Alzheimers Dis"},{"key":"2025070715514440400_awaf037-B25","doi-asserted-by":"crossref","first-page":"4520","DOI":"10.1093\/brain\/awad194","article-title":"Characteristics of amnestic patients with hypometabolism patterns suggestive of Lewy body pathology","volume":"146","author":"Silva-Rodr\u00edguez","year":"2023","journal-title":"Brain"},{"key":"2025070715514440400_awaf037-B26","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1038\/s41596-022-00787-3","article-title":"Seed amplification assay for the detection of pathologic alpha-synuclein aggregates in cerebrospinal fluid","volume":"18","author":"Concha-Marambio","year":"2023","journal-title":"Nat Protoc"},{"key":"2025070715514440400_awaf037-B27","doi-asserted-by":"crossref","first-page":"5114","DOI":"10.1002\/alz.13858","article-title":"A cross-sectional study of \u03b1-synuclein seed amplification assay in Alzheimer\u2019s disease neuroimaging initiative: Prevalence and associations with Alzheimer\u2019s disease biomarkers and cognitive function","volume":"20","author":"Tosun","year":"2024","journal-title":"Alzheimers Dement"},{"key":"2025070715514440400_awaf037-B28","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.nic.2005.09.008","article-title":"The Alzheimer\u2019s disease neuroimaging initiative","volume":"15","author":"Mueller","year":"2005","journal-title":"Neuroimaging Clin N Am"},{"key":"2025070715514440400_awaf037-B29","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1212\/WNL.0000000000012588","article-title":"MCI criteria in ADNI: Meeting biological expectations","volume":"97","author":"Petersen","year":"2021","journal-title":"Neurology"},{"key":"2025070715514440400_awaf037-B30","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","article-title":"The diagnosis of dementia due to Alzheimer\u2019s disease: Recommendations from the national institute on aging-Alzheimer\u2019s association workgroups on diagnostic guidelines for Alzheimer\u2019s disease","volume":"7","author":"McKhann","year":"2011","journal-title":"Alzheimers Dement"},{"key":"2025070715514440400_awaf037-B31","doi-asserted-by":"crossref","first-page":"e1229","DOI":"10.1212\/WNL.0000000000012513","article-title":"Associations of fully automated CSF and novel plasma biomarkers with Alzheimer disease neuropathology at autopsy","volume":"97","author":"Grothe","year":"2021","journal-title":"Neurology"},{"key":"2025070715514440400_awaf037-B32","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1038\/s41591-023-02449-7","article-title":"Clinical effects of Lewy body pathology in cognitively impaired individuals","volume":"29","author":"Quadalti","year":"2023","journal-title":"Nat Med"},{"key":"2025070715514440400_awaf037-B33","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1080\/13854046.2015.1119312","article-title":"How do scores on the ADAS-cog, MMSE, and CDR-SOB correspond?","volume":"29","author":"Balsis","year":"2015","journal-title":"Clin Neuropsychol."},{"key":"2025070715514440400_awaf037-B34","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1007\/s11682-012-9186-z","article-title":"Development and assessment of a composite score for memory in the Alzheimer\u2019s disease neuroimaging initiative (ADNI)","volume":"6","author":"Crane","year":"2012","journal-title":"Brain Imaging Behav."},{"key":"2025070715514440400_awaf037-B35","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s11682-012-9176-1","article-title":"A composite score for executive functioning, validated in Alzheimer\u2019s disease neuroimaging initiative (ADNI) participants with baseline mild cognitive impairment","volume":"6","author":"Gibbons","year":"2012","journal-title":"Brain Imaging Behav."},{"key":"2025070715514440400_awaf037-B36","doi-asserted-by":"crossref","first-page":"e12072","DOI":"10.1002\/trc2.12072","article-title":"Development and validation of language and visuospatial composite scores in ADNI","volume":"6","author":"Choi","year":"2020","journal-title":"A&D Transl Res & Clin Interv"},{"key":"2025070715514440400_awaf037-B37","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s13195-021-00785-9","article-title":"Data-driven FDG-PET subtypes of Alzheimer\u2019s disease-related neurodegeneration","volume":"13","author":"Levin","year":"2021","journal-title":"Alz Res Therapy"},{"key":"2025070715514440400_awaf037-B38","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1212\/WNL.44.12.2308","article-title":"The neuropsychiatric inventory: Comprehensive assessment of psychopathology in dementia","volume":"44","author":"Cummings","year":"1994","journal-title":"Neurology"},{"key":"2025070715514440400_awaf037-B39","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1176\/jnp.12.2.233","article-title":"Validation of the NPI-Q, a brief clinical form of the neuropsychiatric inventory","volume":"12","author":"Kaufer","year":"2000","journal-title":"JNP"},{"key":"2025070715514440400_awaf037-B40","doi-asserted-by":"crossref","first-page":"117229","DOI":"10.1016\/j.neuroimage.2020.117229","article-title":"Intensity normalization methods in brain FDG-PET quantification","volume":"222","author":"L\u00f3pez-Gonz\u00e1lez","year":"2020","journal-title":"NeuroImage"},{"key":"2025070715514440400_awaf037-B41","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.2967\/jnumed.109.065870","article-title":"The 18 F-FDG PET cingulate island sign and comparison to 123 I-\u03b2-CIT SPECT for diagnosis of dementia with Lewy bodies","volume":"50","author":"Lim","year":"2009","journal-title":"J Nucl Med"},{"key":"2025070715514440400_awaf037-B42","doi-asserted-by":"crossref","first-page":"102267","DOI":"10.1016\/j.nicl.2020.102267","article-title":"Evaluating 2-[18F]FDG-PET in differential diagnosis of dementia using a data-driven decision model","volume":"27","author":"Gjerum","year":"2020","journal-title":"Neuroimage Clin."},{"key":"2025070715514440400_awaf037-B43","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1212\/WNL.0000000000000734","article-title":"Dementia with Lewy bodies: Basis of cingulate island sign","volume":"83","author":"Graff-Radford","year":"2014","journal-title":"Neurology"},{"key":"2025070715514440400_awaf037-B44","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1552-6569.2010.00543.x","article-title":"Sex- and age-related differences in brain FDG metabolism of healthy adults: An SPM analysis","volume":"22","author":"Hsieh","year":"2012","journal-title":"J Neuroimaging."},{"key":"2025070715514440400_awaf037-B45","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1007\/s00259-018-3985-4","article-title":"Impact of plasma glucose level on the pattern of brain FDG uptake and the predictive power of FDG PET in mild cognitive impairment","volume":"45","author":"Apostolova","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2025070715514440400_awaf037-B46","doi-asserted-by":"crossref","first-page":"863","DOI":"10.3389\/fpsyg.2013.00863","article-title":"Calculating and reporting effect sizes to facilitate cumulative science: A practical primer for t-tests and ANOVAs","volume":"4","author":"Lakens","year":"2013","journal-title":"Front Psychol"},{"key":"2025070715514440400_awaf037-B47","first-page":"2755","article-title":"Molecular properties underlying regional vulnerability to Alzheimer\u2019s disease pathology","volume":"141","author":"Grothe","year":"2018","journal-title":"Brain"},{"key":"2025070715514440400_awaf037-B48","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1002\/alz.13658","article-title":"Investigating alpha-synuclein co-pathology in Alzheimer\u2019s disease by means of cerebrospinal fluid alpha-synuclein seed amplification assay","volume":"20","author":"Bellomo","year":"2024","journal-title":"Alzheimers Dementia"},{"key":"2025070715514440400_awaf037-B49","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1097\/01.jnen.0000225908.90052.07","article-title":"Alzheimer disease with amygdala Lewy bodies: A distinct form of alpha-synucleinopathy","volume":"65","author":"Uchikado","year":"2006","journal-title":"J Neuropathol Exp Neurol"},{"key":"2025070715514440400_awaf037-B50","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s13195-018-0417-4","article-title":"Sex ratio in dementia with Lewy bodies balanced between Alzheimer\u2019s disease and Parkinson\u2019s disease dementia: A cross-sectional study","volume":"10","author":"Mouton","year":"2018","journal-title":"Alz Res Therapy"},{"key":"2025070715514440400_awaf037-B51","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1007\/s11357-023-00883-6","article-title":"Involvement of ApoE4 in dementia with Lewy bodies in the prodromal and demented stages: Evaluation of the Strasbourg cohort","volume":"46","author":"Bousiges","year":"2024","journal-title":"GeroScience"},{"key":"2025070715514440400_awaf037-B52","doi-asserted-by":"crossref","first-page":"120815","DOI":"10.1016\/j.jns.2023.120815","article-title":"Clinical characteristics of pathological confirmed prodromal dementia with Lewy bodies","volume":"453","author":"Ting","year":"2023","journal-title":"J Neurol Sci."},{"key":"2025070715514440400_awaf037-B53","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1177\/0004867419835029","article-title":"Dementia with Lewy bodies: Challenges in the diagnosis and management","volume":"53","author":"Chin","year":"2019","journal-title":"Aust N Z J Psychiatry"},{"key":"2025070715514440400_awaf037-B54","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1159\/000333072","article-title":"Early and presenting symptoms of dementia with Lewy bodies","volume":"32","author":"Auning","year":"2011","journal-title":"Dement Geriatr Cogn Disord"},{"key":"2025070715514440400_awaf037-B55","doi-asserted-by":"crossref","first-page":"1024995","DOI":"10.3389\/fneur.2022.1024995","article-title":"Characteristics of initial symptoms in patients with dementia with Lewy body disease","volume":"13","author":"Fei","year":"2022","journal-title":"Front Neurol"},{"key":"2025070715514440400_awaf037-B56","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.dadm.2017.12.001","article-title":"Hospitalization in people with dementia with Lewy bodies: Frequency, duration, and cost implications","volume":"10","author":"Mueller","year":"2018","journal-title":"Alz & Dem Diag Ass & Dis Mo"},{"key":"2025070715514440400_awaf037-B57","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.arr.2019.01.005","article-title":"Survival time and differences between dementia with Lewy bodies and Alzheimer\u2019s disease following diagnosis: A meta-analysis of longitudinal studies","volume":"50","author":"Mueller","year":"2019","journal-title":"Ageing Res Rev."},{"key":"2025070715514440400_awaf037-B58","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/alz.12814","article-title":"Dementia with Lewy bodies: Impact of co-pathologies and implications for clinical trial design","volume":"19","author":"Toledo","year":"2023","journal-title":"Alzheimers Dement"},{"key":"2025070715514440400_awaf037-B59","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1002\/mds.26668","article-title":"Alzheimer\u2019s disease cerebrospinal fluid biomarkers predict cognitive decline in Lewy body dementia","volume":"31","author":"Abdelnour","year":"2016","journal-title":"Mov Disord"},{"key":"2025070715514440400_awaf037-B60","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S1474-4422(16)30291-5","article-title":"Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: A retrospective analysis","volume":"16","author":"Irwin","year":"2017","journal-title":"Lancet Neurol"},{"key":"2025070715514440400_awaf037-B61","doi-asserted-by":"crossref","first-page":"632","DOI":"10.2967\/jnumed.116.179903","article-title":"18 F-FDG PET in posterior cortical atrophy and dementia with Lewy Bodies","volume":"58","author":"Whitwell","year":"2017","journal-title":"J Nucl Med"},{"key":"2025070715514440400_awaf037-B62","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/S1474-4422(11)70289-7","article-title":"Posterior cortical atrophy","volume":"11","author":"Crutch","year":"2012","journal-title":"Lancet Neurol."},{"key":"2025070715514440400_awaf037-B63","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1212\/01.WNL.0000158423.05224.7F","article-title":"The pathology of the substantia nigra in Alzheimer disease with extrapyramidal signs","volume":"64","author":"Burns","year":"2005","journal-title":"Neurology"},{"key":"2025070715514440400_awaf037-B64","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1136\/jnnp.52.2.193","article-title":"The substantia nigra and ventral tegmental area in Alzheimer\u2019s disease and Down\u2019s syndrome","volume":"52","author":"Gibb","year":"1989","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2025070715514440400_awaf037-B65","doi-asserted-by":"crossref","first-page":"a006189","DOI":"10.1101\/cshperspect.a006189","article-title":"Neuropathological alterations in Alzheimer Disease","volume":"1","author":"Serrano-Pozo","year":"2011","journal-title":"Cold Spring Harb Perspect Med."},{"key":"2025070715514440400_awaf037-B66","doi-asserted-by":"crossref","first-page":"4448","DOI":"10.1093\/brain\/awac084","article-title":"Interrelation of striatal dopamine, brain metabolism and cognition in dementia with Lewy bodies","volume":"145","author":"Yoo","year":"2022","journal-title":"Brain"},{"key":"2025070715514440400_awaf037-B67","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1136\/jnnp-2020-324606","article-title":"123I-FP-CIT SPECT in dementia with Lewy bodies, Parkinson\u2019s disease and Alzheimer\u2019s disease: A new quantitative analysis of autopsy confirmed cases","volume":"92","author":"Oliveira","year":"2021","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2025070715514440400_awaf037-B68","doi-asserted-by":"crossref","first-page":"365","DOI":"10.5607\/en21025","article-title":"Diffusion measure changes of substantia Nigra subregions and the ventral tegmental area in newly diagnosed Parkinson\u2019s disease","volume":"30","author":"Shim","year":"2021","journal-title":"Exp Neurobiol"},{"key":"2025070715514440400_awaf037-B69","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1148\/radiol.2021203341","article-title":"Imaging the substantia Nigra in Parkinson disease and other parkinsonian syndromes","volume":"300","author":"Bae","year":"2021","journal-title":"Radiology"}],"container-title":["Brain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/brain\/advance-article-pdf\/doi\/10.1093\/brain\/awaf037\/61721098\/awaf037.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/brain\/article-pdf\/148\/7\/2441\/61721098\/awaf037.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/brain\/article-pdf\/148\/7\/2441\/61721098\/awaf037.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T19:51:57Z","timestamp":1751917917000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/brain\/article\/148\/7\/2441\/7994281"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,31]]},"references-count":69,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,1,31]]},"published-print":{"date-parts":[[2025,7,7]]}},"URL":"https:\/\/doi.org\/10.1093\/brain\/awaf037","relation":{},"ISSN":["0006-8950","1460-2156"],"issn-type":[{"value":"0006-8950","type":"print"},{"value":"1460-2156","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,7]]},"published":{"date-parts":[[2025,1,31]]}}}